Obio Technology Shanghai Corp

Obio Technology Shanghai Corp EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Obio Technology Shanghai Corp (688238.SS) as of Nov 19, 2026 is -20.70. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -20.69 — a change of 0.07% (lower).

EV/FCF

-20.70

YoY

0.07%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Obio Technology Shanghai Corp is 2025 -20.70 . EV/FCF (Enterprise Value to Free Cash Flow) of Obio Technology Shanghai Corp was 2024 -20.69 . It decreases by 0.07% lower compared to the previous year.

The Obio Technology Shanghai Corp EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-79.23 CNY
Jan 1, 2019
-78.00 CNY
Jan 1, 2020
-136.93 CNY
Jan 1, 2021
-30.78 CNY
Jan 1, 2022
-10.03 CNY
Jan 1, 2023
-7.45 CNY
Jan 1, 2024
-20.69 CNY
Jan 1, 2025
-20.70 CNY
The Obio Technology Shanghai Corp EV/FCF history
YEAREV/FCFYoY
-20.70+0.07%
-20.69+177.82%
-7.45-25.78%
-10.03-67.40%
-30.78-77.52%
-136.93+75.55%
-78.00-1.55%
-79.23—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Obio Technology Shanghai Corp Stock analysis

What does Obio Technology Shanghai Corp do? Obio Technology Shanghai Corp Ltd provides biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO services. The company offers contract research organization (CRO) services including gene therapy vector development and gene function research for gene therapy basic research, as well as contract research and development production organization (CDMO) services for gene drug R&D, such as pharmaceutical research and clinical sample production. It serves European and American markets and the domestic market with its CRO and CDMO offerings. The firm generates revenue through CRO services like gene therapy vector development and gene function research, and CDMO services including pharmaceutical research and clinical sample production. Its primary clients are companies involved in gene therapy and gene drug development, focusing on the European and American markets and domestic segments. The company's services support the research and development phases of gene therapy and gene drug products. Obio Technology Shanghai Corp Ltd's business model centers on providing specialized research and production services for gene therapy and gene drug development. By offering both CRO and CDMO services, it addresses key needs in the gene therapy industry, particularly in vector development and clinical sample production, targeting pharmaceutical companies and research institutions in Europe, America, and China. Obio Technology Shanghai Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Obio Technology Shanghai Corp stock

EV/FCF (Enterprise Value to Free Cash Flow) of Obio Technology Shanghai Corp is -20.70 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Obio Technology Shanghai Corp changed from -20.69 to -20.70, representing a 0.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Obio Technology Shanghai Corp since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Obio Technology Shanghai Corp with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Obio Technology Shanghai Corp

All Key Metrics — Obio Technology Shanghai Corp